Published in Proc Natl Acad Sci U S A on November 01, 1987
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J (1991) 5.39
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A (1991) 5.31
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol (1995) 2.82
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 2.59
High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol (1989) 2.45
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A (1995) 2.09
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol (1990) 2.03
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J (1995) 2.02
Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J (1994) 2.02
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A (1991) 1.99
Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.96
Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A (1989) 1.86
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A (1998) 1.83
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med (2009) 1.70
Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol (1993) 1.70
Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus. Proc Natl Acad Sci U S A (1990) 1.67
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65
Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A (1991) 1.65
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol (1990) 1.58
p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A (1991) 1.56
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol (1992) 1.56
Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol (1996) 1.47
p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol (1998) 1.44
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol (1993) 1.42
The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol (1997) 1.40
Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A (1990) 1.39
Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology. Ann Surg (1990) 1.39
Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol (1991) 1.39
Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest (1990) 1.38
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res (1995) 1.37
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer (1992) 1.36
Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci U S A (1992) 1.33
Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol (1997) 1.30
The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J (1998) 1.26
Characterization of the human p53 gene promoter. Mol Cell Biol (1989) 1.25
Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol (1991) 1.25
Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J (1993) 1.25
Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer (1992) 1.24
p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer (1990) 1.24
p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc Natl Acad Sci U S A (1997) 1.18
A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc Natl Acad Sci U S A (1992) 1.16
Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials (2008) 1.16
Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A (2000) 1.15
Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. EMBO J (1990) 1.12
Integration of Friend murine leukemia virus into both alleles of the p53 oncogene in an erythroleukemic cell line. J Virol (1988) 1.10
Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest (1990) 1.10
Adenovirus E1A proteins inhibit activation of transcription by p53. Mol Cell Biol (1996) 1.09
The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol (1993) 1.09
Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A (1994) 1.08
Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci U S A (1992) 1.08
Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J Virol (1988) 1.07
Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif. Proc Natl Acad Sci U S A (1991) 1.06
Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1993) 1.05
p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer (1993) 1.04
Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein. Proc Natl Acad Sci U S A (1993) 1.01
Mutation of the serine 312 phosphorylation site does not alter the ability of mouse p53 to inhibit simian virus 40 DNA replication in vivo. J Virol (1990) 1.00
The p53 complex from monkey cells modulates the biochemical activities of simian virus 40 large T antigen. J Virol (1989) 0.99
Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res (1996) 0.99
TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget (2015) 0.98
Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci U S A (1994) 0.98
p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J (1998) 0.98
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer (2011) 0.96
Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer (1991) 0.96
Molecular mechanisms of cancer. West J Med (1991) 0.95
Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A (2011) 0.95
Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol (2009) 0.94
Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol (1994) 0.94
TAF6delta controls apoptosis and gene expression in the absence of p53. PLoS One (2008) 0.93
Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol (1994) 0.93
Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol (2002) 0.92
Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J Virol (2008) 0.91
Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem (2011) 0.90
Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells. BMB Rep (2013) 0.90
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest (1992) 0.90
An intron binding protein is required for transformation ability of p53. Nucleic Acids Res (1991) 0.88
Excess wild-type p53 blocks initiation and maintenance of simian virus 40 transformation. Mol Cell Biol (1991) 0.87
Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone (2006) 0.87
Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol (1990) 0.87
The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res (2010) 0.86
Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol (1994) 0.86
CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest (1998) 0.85
Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest (1992) 0.85
P53 mutations in gastric carcinomas. Br J Cancer (1992) 0.85
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions. Mol Diagn Ther (2013) 0.85
Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol Cell Biol (1997) 0.83
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (1985) 5.69
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Human p53 gene localized to short arm of chromosome 17. Nature (1986) 4.67
Characterization of the human p53 gene. Mol Cell Biol (1986) 4.33
Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature (1984) 4.24
Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci U S A (1981) 3.99
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. Proc Natl Acad Sci U S A (1983) 3.53
The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology (1979) 3.33
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol (1985) 3.09
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol (1984) 2.88
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Interaction of Candida albicans with human leukocytes and serum. J Bacteriol (1969) 9.19
Consequences of reducing nonresponse in a national telephone survey. Public Opin Q (2000) 7.67
Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest (1969) 7.61
Conduction and selectivity in potassium channels. J Membr Biol (1983) 6.41
Open-state substructure of single chloride channels from Torpedo electroplax. Philos Trans R Soc Lond B Biol Sci (1982) 5.26
Charybdotoxin, a protein inhibitor of single Ca2+-activated K+ channels from mammalian skeletal muscle. Nature (1985) 4.95
An improved technique for multiple organ harvesting. Surg Gynecol Obstet (1987) 4.73
Human p53 gene localized to short arm of chromosome 17. Nature (1986) 4.67
Expression of cellular oncogenes in human malignancies. Science (1984) 4.48
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44
Nonequilibrium gating and voltage dependence of the ClC-0 Cl- channel. J Gen Physiol (1996) 4.24
Discrete Ba2+ block as a probe of ion occupancy and pore structure in the high-conductance Ca2+ -activated K+ channel. J Gen Physiol (1988) 4.05
Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol (1991) 3.97
Phagocytosis by human monocytes. Blood (1968) 3.96
Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet (1986) 3.93
Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science (1978) 3.91
Fertilization-independent seed development in Arabidopsis thaliana. Proc Natl Acad Sci U S A (1997) 3.87
The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest (1986) 3.87
Potassium blocks barium permeation through a calcium-activated potassium channel. J Gen Physiol (1988) 3.82
Single chloride channels from Torpedo electroplax. Activation by protons. J Gen Physiol (1983) 3.76
Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase. JAMA (2000) 3.64
Mechanism of charybdotoxin block of the high-conductance, Ca2+-activated K+ channel. J Gen Physiol (1988) 3.48
Homodimeric architecture of a ClC-type chloride ion channel. Nature (1996) 3.47
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol (1991) 3.45
Single streptomyces lividans K(+) channels: functional asymmetries and sidedness of proton activation. J Gen Physiol (1999) 3.42
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
The role of the vitamin D endocrine system in health and disease. N Engl J Med (1989) 3.37
Consensus statement on the live organ donor. JAMA (2000) 3.29
Multi-ion conduction and selectivity in the high-conductance Ca++-activated K+ channel from skeletal muscle. Biophys J (1986) 3.24
KcsA: it's a potassium channel. J Gen Physiol (2001) 3.23
Dimeric structure of single chloride channels from Torpedo electroplax. Proc Natl Acad Sci U S A (1984) 3.22
Ionic selectivity, saturation, and block in a K+-selective channel from sarcoplasmic reticulum. J Gen Physiol (1980) 3.16
In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. III. The kinetics of V region mutation and selection in germinal center B cells. J Exp Med (1993) 3.13
The interaction of human monocytes and lymphocytes. J Exp Med (1968) 2.93
Language discrimination by human newborns and by cotton-top tamarin monkeys. Science (2000) 2.89
Charybdotoxin block of single Ca2+-activated K+ channels. Effects of channel gating, voltage, and ionic strength. J Gen Physiol (1988) 2.87
Bis-quaternary ammonium blockers as structural probes of the sarcoplasmic reticulum K+ channel. J Gen Physiol (1982) 2.87
Amygdalin (Laetrile): effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow. Cancer Treat Rep (1980) 2.86
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med (1997) 2.84
Interpretation and quantification of immunostains. Am J Surg Pathol (2001) 2.82
Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Pediatrics (1995) 2.82
Steady-state coupling of ion-channel conformations to a transmembrane ion gradient. Science (1990) 2.80
Silver as a probe of pore-forming residues in a potassium channel. Science (1995) 2.78
Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol (2000) 2.76
Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. Science (1989) 2.75
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
Functional reconstitution of a prokaryotic K+ channel. J Gen Physiol (1998) 2.66
A voltage-gated anion channel from the electric organ of Torpedo californica. J Biol Chem (1979) 2.65
Voltage-gated cation conductance channel from fragmented sarcoplasmic reticulum: steady-state electrical properties. J Membr Biol (1978) 2.57
Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature (1986) 2.56
The charybdotoxin receptor of a Shaker K+ channel: peptide and channel residues mediating molecular recognition. Neuron (1994) 2.55
Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res (2001) 2.53
Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem (1999) 2.47
The human alveolar macrophage: isolation, cultivation in vitro, and studies of morphologic and functional characteristics. J Clin Invest (1971) 2.47
Effects of phospholipid surface charge on ion conduction in the K+ channel of sarcoplasmic reticulum. Biophys J (1984) 2.46
Laboratory and bedside evaluation of portable glucose meters. Am J Clin Pathol (1995) 2.35
Human monocytes and macrophages. Interaction with antigen and lymphocytes. J Cell Biol (1970) 2.35
Cyclic 3',5'-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Invest (1971) 2.35
Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science (1986) 2.33
Identification of the colony-stimulating cell in human peripheral blood. J Clin Invest (1972) 2.33
Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol (1992) 2.32
A voltage-dependent chloride conductance channel from Torpedo electroplax membrane. Ann N Y Acad Sci (1980) 2.26
Batrachotoxin-activated Na+ channels in planar lipid bilayers. Competition of tetrodotoxin block by Na+. J Gen Physiol (1984) 2.26
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
Role of surface electrostatics in the operation of a high-conductance Ca2+-activated K+ channel. Biochemistry (1989) 2.25
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
Human immunodeficiency virus infection in disadvantaged adolescents. Findings from the US Job Corps. JAMA (1991) 2.24
Purification, reconstitution, and subunit composition of a voltage-gated chloride channel from Torpedo electroplax. Biochemistry (1994) 2.21
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Food service and foods and beverages available at school: results from the School Health Policies and Programs Study 2000. J Sch Health (2001) 2.16
Allosteric effects of Mg2+ on the gating of Ca2+-activated K+ channels from mammalian skeletal muscle. J Exp Biol (1986) 2.14
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
High-level expression, functional reconstitution, and quaternary structure of a prokaryotic ClC-type chloride channel. J Gen Physiol (1999) 2.12
Helical structure and packing orientation of the S2 segment in the Shaker K+ channel. J Gen Physiol (1999) 2.10
A potential transcriptional activation element in the p53 protein. Oncogene (1990) 2.07
Thermodynamic and kinetic studies of the gating behavior of a K+-selective channel from the sarcoplasmic reticulum membrane. J Gen Physiol (1980) 2.06
Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia (2007) 2.06
Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol (2001) 2.05
A K+-selective, three-state channel from fragmented sarcoplasmic reticulum of frog leg muscle. J Membr Biol (1981) 2.04
Ca++-induced fusion of fragmented sarcoplasmic reticulum with artificial planar bilayers. J Membr Biol (1976) 2.04
The response of human leucocyte cultures to stimulation by tuberculin and phytohaemagglutinin measured by the uptake of radioactive thymidine. Clin Exp Immunol (1967) 2.01
1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol (1984) 2.01
Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood (1983) 2.01
Conduction and block by organic cations in a K+-selective channel from sarcoplasmic reticulum incorporated into planar phospholipid bilayers. J Gen Physiol (1982) 2.00
Mechanism of charybdotoxin block of a voltage-gated K+ channel. Biophys J (1993) 1.99
Monocyte function in man. J Immunol (1977) 1.99
Health service use among low-risk newborns after early discharge with and without nurse home visiting. J Am Board Fam Pract (1997) 1.97
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene (2008) 1.97
gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem Biophys Res Commun (1985) 1.97
Human myeloid leukemia cell lines: a review. Blood (1980) 1.96
Absence of WAF1 mutations in a variety of human malignancies. Blood (1994) 1.95
Trapping single ions inside single ion channels. Biophys J (1987) 1.94
Tetrameric stoichiometry of a prokaryotic K+ channel. Biochemistry (1997) 1.94
p27/Kip1 mutation found in breast cancer. Cancer Res (1996) 1.94
More on epidural needle wings. Anaesthesia (2006) 1.92